Antibodies is how a vaccine brings out your immune response. If your immune response is 67% less in magnitude, the virus is going to find it easier to attack your body. This is simple logic, and this is exactly why AZ, Vaxart, and other vaccine candidates - with studies already completed - have been prevented from being used in some instances.
Feel free to reference an author or a scientific opinion claiming that the Pfizer vaccine will still remain 95% or similarly effective against the South African variant as against the others.
Your still missing the point. I don't know how to make it more clear. We don't know how much antibody someone needs to be protected. 1/3 may be enough. In fact, the coauthor thinks it will be significantly more than needed.
Think of it this way - if we didn't have the original virus to compare it to, we might be saying, "this is great, we are getting antibodies at X level, now let's see if that is sufficient to provide protection." It is only because we have a comparator that it may appear to be disappointing. But, it
may not matter that it produces 2/3 less antibodies for the variant.
You moved the goal posts by bringing in 95%. Nowhere did I claim that it would be 95% effective. I claimed
we don't know how effective it will be yet, versus your claim that it would have "low" efficacy. Where is your source for that? And again, as pointed out by the coauthor of the study, lower antibody response is not necessarily the same thing as low efficacy in protecting people (the only efficacy that matters for a vaccine).
The co-author feels the vaccine will be "protective" against the variant. We don't know what he means by that, but there is no indication of a belief that it will remain as effective as it has against the prior variants. The study's formal statement:
I don't know what else "protective" may mean if not effective. What else is a vaccine supposed to do if not protect individuals? You claimed the vaccine was going to provide "low" efficacy (
i.e. offer low protection against the variant). He disagrees with you and says he thinks it will be protective:
We don’t know what the minimum neutralizing number is. We don’t have that cutoff line,” he said, adding that he suspects the immune response observed is likely to be significantly above where it needs to be to provide protection."
Furthermore, the article states this:
Because there is no established benchmark yet to determine what level of antibodies are needed to protect against the virus, it is unclear whether that two-thirds reduction will render the vaccine ineffective against the variant spreading around the world.
Efficacy is exactly what is being discussed and what is unknown.
Your citation doesn't add anything new to the conversation. It points out there were less neutralizing antibodies. We agree on that. But, again, you can have less neutralizing antibodies and still prevent cases or severe cases/death. Maybe even at the same efficacy level. Nobody knows yet. That's the point.
Also,
CNN Health in interpreting that matter the same as me:
Lab studies suggest Pfizer, Moderna vaccines can protect against coronavirus variant
A new report published in the New England Journal of Medicine on Wednesday suggests that Pfizer-BioNTech's Covid-19 vaccine can protect people against concerning new coronavirus variants, including one first seen in South Africa called B.1.351.
For the study, researchers at Pfizer and the University of Texas Medical Branch genetically engineered versions of the virus to carry some of the mutations found in B.1.351. They tested them against blood samples taken from 15 people who had received two doses of the Pfizer/BioNTech vaccine as part of a clinical trial.
While the blood serum samples produced less neutralizing antibody activity, it was still enough to neutralize the virus, they wrote in a letter to the journal. This is in line with other studies. And it's well within what is seen with other viruses, one of the researchers said.
"The reduction in the levels of neutralization against the South African variant of about 2/3 is fairly small compared to variations in neutralization levels generated by vaccines against other viruses that have even more variability in their protein sequences than SARS-CoV-2," Weaver added.
P.S. Moderna is reporting the same thing:
Separately, a team at the National Institutes of Health and Moderna published a letter in the same journal outlining findings from an experiment they reported last month. They also reported a reduction in the antibody response to viruses genetically engineered to look like the B.1.351 variant -- but not enough of a reduction to make the vaccine work any less effectively.
Since they used the word "effective" instead of "protection," maybe you won't argue about that one?